Technical Analysis for BCAB - BioAtla, Inc.

Grade Last Price % Change Price Change
D 3.46 14.95% 0.45
BCAB closed up 14.95 percent on Wednesday, March 27, 2024, on 4.9 times normal volume.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Earnings Movers Other 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 20 DMA Bullish 14.95%
Crossed Above 200 DMA Bullish 14.95%

   Recent Intraday Alerts

Alert Time
Up 2 ATRs about 20 hours ago
60 Minute Opening Range Breakout about 21 hours ago
Up 10% about 23 hours ago
10x Volume Pace about 23 hours ago
Possible Pocket Pivot about 23 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Health Care Tumor Cancer Immunotherapy Monoclonal Antibodies Non Small Cell Lung Cancer Melanoma Small Cell Lung Cancer Targeted Therapy Bladder Cancer Hepatocellular Carcinoma NSCLC Non Small Cell Lung Carcinoma Renal Cell Carcinoma Cervical Cancer Gastric Cancer

Is BCAB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.068
52 Week Low 1.24
Average Volume 457,306
200-Day Moving Average 2.33
50-Day Moving Average 2.47
20-Day Moving Average 2.66
10-Day Moving Average 2.56
Average True Range 0.28
RSI (14) 70.33
ADX 18.31
+DI 38.87
-DI 12.32
Chandelier Exit (Long, 3 ATRs) 2.84
Chandelier Exit (Short, 3 ATRs) 3.07
Upper Bollinger Bands 3.21
Lower Bollinger Band 2.10
Percent B (%b) 1.22
BandWidth 41.65
MACD Line 0.08
MACD Signal Line 0.02
MACD Histogram 0.058
Fundamentals Value
Market Cap 165.86 Million
Num Shares 47.9 Million
EPS -2.65
Price-to-Earnings (P/E) Ratio -1.31
Price-to-Sales 989.22
Price-to-Book 1.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.45
Resistance 3 (R3) 4.41 4.04 4.28
Resistance 2 (R2) 4.04 3.79 4.06 4.23
Resistance 1 (R1) 3.75 3.63 3.89 3.79 4.17
Pivot Point 3.38 3.38 3.45 3.40 3.38
Support 1 (S1) 3.09 3.13 3.24 3.13 2.75
Support 2 (S2) 2.72 2.97 2.74 2.69
Support 3 (S3) 2.43 2.72 2.64
Support 4 (S4) 2.47